2026 Biocompatibility Updates: A Guide for Medical Device Makers

With significant updates to global biocompatibility standards, including ISO 10993, anticipated around 2026, medical device manufacturers face a critical window to prepare. A reactive approach—waiting for the final standards to be published—can lead to costly delays, additional testing on marketed products, and challenges with new submissions. A proactive strategy, however, allows companies to align their biological safety evaluation processes with the evolving "state-of-the-art," de-risk their device portfolios, and ensure smoother regulatory reviews. This involves more than just monitoring standards committees. A robust preparatory strategy requires a comprehensive review of existing devices, a critical evaluation of supply chain documentation, and a forward-looking approach to testing plans for new products. By systematically performing gap analyses, reinforcing supplier data, and future-proofing development, manufacturers can build a strong foundation for compliance and demonstrate a commitment to patient safety that aligns with regulator expectations. ### Key Points * **Proactive Gap Analysis is Essential:** Manufacturers should not wait for final standard updates. Instead, they should immediately begin a gap analysis of their existing device portfolio's biological evaluation documentation against anticipated changes, such as increased emphasis on chemical characterization. * **Focus on Material and Chemical Data:** The trend in biocompatibility is moving toward a deeper understanding of device materials and their chemical constituents. Future success will depend on robust chemical characterization data and comprehensive toxicological risk assessments. * **Strengthen Supply Chain Controls:** Obtaining detailed material composition and manufacturing process information from suppliers is no longer optional. This data is fundamental to a modern biological risk assessment and must be actively sought and documented. * **Future-Proof New Development:** For devices currently in development, biological evaluation plans should be designed to meet both current and likely future requirements. This may mean defaulting to more comprehensive chemical characterization studies, especially for higher-risk devices like long-term implants. * **Document Everything in the QMS:** All proactive efforts—gap analyses, supplier communications, and testing rationale—must be meticulously documented within the Quality Management System (QMS), Risk Management File, and Design History File to create a clear, auditable trail for regulators. * **Utilize the Q-Submission Program:** For novel materials or complex biological evaluation strategies, engaging the FDA early via the Q-Submission program is a critical step to gain alignment on testing plans before significant resources are invested. ## Understanding the Potential Shifts in Biocompatibility Evaluation While the exact text of future standards is not yet finalized, the direction of change is clear, reflecting trends in regulatory science. The focus is shifting from a rigid, checklist-based approach to a more holistic, risk-based evaluation. Key anticipated shifts include: * **Increased Emphasis on Chemical Characterization:** Regulators increasingly expect manufacturers to thoroughly understand the chemical components of their devices and what might leach out during clinical use. This means a greater reliance on analytical chemistry techniques (extractables and leachables testing) as a primary step in the evaluation. * **Toxicological Risk Assessment (TRA) as a Core Element:** With robust chemical characterization data, a TRA can be used to assess the risk of each identified compound. A well-executed TRA can provide a powerful justification for why certain biological endpoints are not relevant, potentially reducing the need for costly and time-consuming animal testing. * **Evaluation of Novel and Transient Materials:** The updates will likely include more specific guidance on evaluating new categories of materials, such as absorbable materials, nanomaterials, and materials used in transient contact with the body. ## Step 1: Proactive Gap Analysis of Existing Device Portfolios Manufacturers should not limit their focus to new devices. Marketed products supported by older biocompatibility data may be vulnerable to future scrutiny. A proactive gap analysis is a systematic way to identify and mitigate this risk. ### How to Conduct a Portfolio Gap Analysis: 1. **Inventory and Prioritize:** Create a list of all marketed devices. Prioritize them based on risk class, patient contact type and duration, and the age of their existing biocompatibility data. Devices with permanent patient contact or those relying on data from over a decade ago should be at the top of the list. 2. **Review Existing Biological Evaluation Reports (BERs):** For each high-priority device, critically review the existing BER. Assess the strength of the rationale and supporting data against potential future requirements. * **Material Information:** How detailed is the material information? Is it generic (e.g., "medical-grade silicone") or specific (e.g., including supplier, grade, and processing additives)? * **Chemical Data:** Was any chemical characterization performed? If not, was the justification for its absence well-documented and scientifically sound by today's standards? * **Reliance on Animal Testing:** Does the file rely heavily on historical in-vivo (animal) test reports without a strong supporting chemical risk assessment? This could be a significant gap. 3. **Identify Potential Gaps:** Document specific areas where the existing data may fall short. Common gaps include: * Lack of chemical characterization data for a long-term implant. * Inadequate information on colorants, additives, or processing aids. * Justifications for waiving tests that are no longer considered sufficient. 4. **Develop a Risk-Based Remediation Plan:** For each identified gap, create a plan. This does not always mean re-testing. The plan could include: * Contacting the raw material supplier to obtain more detailed composition data. * Conducting a new literature review to support the safety of existing materials. * Performing a limited, targeted chemical characterization study on the finished device to fill a critical data gap. ## Step 2: Reinforcing the Supply Chain for Deeper Material Insight A device's biological safety is fundamentally tied to its raw materials. As regulators demand more transparency, manufacturers must demand the same from their suppliers. ### What to Request from Suppliers: * **Complete Material Composition:** Request a full, quantitative breakdown of the material formulation, including monomers, catalysts, additives, and colorants. * **Manufacturing Process Details:** Understand how the material is made. Information on polymerization methods, solvents used, and sterilization processes can inform the biological risk assessment. * **Known Impurities and Residuals:** Ask for data on potential process residuals (e.g., unreacted monomers, catalysts) that could be present in the final material. * **Supplier-Available Testing Data:** Some suppliers may have already conducted extractables studies or other tests on their materials. Requesting and evaluating this data can prevent redundant testing. This information should be formally documented in updated Supplier Quality Agreements to ensure ongoing transparency and change control. ## Step 3: Future-Proofing New Device Development For devices currently in the design and development phase, manufacturers have the opportunity to build a state-of-the-art biological safety evaluation from the ground up. ### Structuring a Future-Proof Biological Evaluation Plan (BEP): A modern BEP should be a comprehensive, risk-based strategy document, not just a list of proposed tests. 1. **Start with a Physical and Chemical Information Foundation:** The BEP should begin with a thorough description of the device, all its material components, and the manufacturing processes. 2. **Default to Chemical Characterization:** For any device with significant patient contact (e.g., more than 24 hours) or those made from novel materials, the plan should include exhaustive chemical characterization as a default first step. 3. **Leverage a Toxicological Risk Assessment:** Plan to use the results of the chemical characterization to conduct a formal TRA. This assessment will determine if the levels of any leachable substances pose an unacceptable toxicological risk. 4. **Justify the Testing Strategy:** The BEP must clearly explain the rationale for every step. If the TRA indicates that all leachable substances are well below safe limits, the plan can include a strong scientific justification for waiving certain in-vivo biological tests. This approach, which aligns with FDA guidance and international standards, is both scientifically robust and efficient. ### Scenario: A Class II Blood-Contacting Device with a Novel Polymer Coating * **The Challenge:** A company is developing a new catheter (a Class II blood-contacting device) that uses a novel polymer coating to improve lubricity. The polymer has no history of use in medical devices. * **A Reactive (Outdated) Approach:** The manufacturer might simply run the standard battery of biocompatibility tests for blood-contacting devices (e.g., cytotoxicity, sensitization, hemocompatibility, systemic toxicity). This approach is risky because if a test fails, the root cause is unknown, leading to costly delays. * **A Proactive (Future-Proofed) Approach:** 1. **Deep Supplier Collaboration:** The manufacturer works with the polymer supplier to get a complete formulation breakdown and details on the coating and sterilization process. 2. **Upfront Chemical Characterization:** An exhaustive extractables and leachables study is performed on the final, sterilized catheter under simulated-use conditions. 3. **Toxicological Risk Assessment:** A qualified toxicologist assesses every compound identified in the study. 4. **Targeted Biological Testing:** The TRA concludes that all but one compound are far below toxicological concern thresholds. The remaining compound is a known irritant, but the predicted exposure level is low. Based on this, the company proposes a targeted testing plan that includes standard hemocompatibility and cytotoxicity tests but provides a strong, risk-based justification for why a long-term systemic toxicity study is not necessary. 5. **Q-Submission:** Given the novel material, the company submits the entire BEP—including the chemical data, TRA, and proposed testing plan—to the FDA via a Q-Submission to gain feedback and alignment before initiating the final tests. ## Step 4: Documenting a State-of-the-Art Approach in the QMS Proactive measures are only valuable if they are properly documented. Regulators need to see not just the final data, but the strategic thinking behind it. All activities related to biocompatibility preparation should be integrated into the QMS. * **Risk Management File (RMF):** The biological risk assessment should be a central part of the RMF, linking material choices to potential patient harms and the controls (e.g., testing) used to mitigate them. * **Design History File (DHF):** The BEP, all test reports, the TRA, and the final BER are critical DHF components. The rationale for the biological evaluation strategy should be clearly articulated. * **Supplier Files:** All communications and documentation received from material suppliers should be maintained and referenced in the device's risk and design files. ## Strategic Considerations and the Role of Q-Submission Adopting a proactive, risk-based biocompatibility strategy is a significant shift for many organizations. It requires closer collaboration between R&D, manufacturing, quality, and regulatory affairs. While it may seem more intensive upfront, this approach ultimately reduces regulatory risk, minimizes the chance of unexpected test failures, and can even accelerate timelines by avoiding redundant animal testing. For any device involving novel materials, challenging patient contact (e.g., neural tissue), or a complex biological evaluation strategy, early engagement with the FDA is paramount. The Q-Submission program allows manufacturers to present their proposed BEP and TRA to the agency for feedback. Gaining FDA alignment on a testing strategy before it is executed can prevent significant delays and rework during the final premarket review. ## Finding and Comparing Biocompatibility Testing Services Providers Successfully navigating this evolving landscape requires a partnership with a qualified testing laboratory. Choosing the right provider is a critical strategic decision. Look for a lab that demonstrates deep expertise not just in routine biological testing, but also in advanced analytical chemistry and toxicological risk assessment. A strong partner will act as a consultant, helping you design a modern, efficient testing strategy rather than simply executing a list of tests. When comparing options, inquire about their experience with new standards, their analytical equipment capabilities, and the qualifications of their toxicologists. To find qualified vetted providers [click here](https://cruxi.ai/regulatory-directories/biocompatibility_testing) and request quotes for free. ## Key FDA References When developing a biocompatibility strategy, sponsors should always refer to the latest official documents and regulations. While specific guidance documents are frequently updated, the following foundational resources are always relevant: * FDA's Biocompatibility Guidance on the Use of International Standard ISO 10993-1. * FDA's Q-Submission Program Guidance. * General requirements for premarket submissions under 21 CFR, such as 21 CFR Part 807 for 510(k) submissions. Sponsors should consult the FDA website for the most current versions of all guidance documents. *** *This article is for general educational purposes only and is not legal, medical, or regulatory advice. For device-specific questions, sponsors should consult qualified experts and consider engaging FDA via the Q-Submission program.* --- *This answer was AI-assisted and reviewed for accuracy by Lo H. Khamis.*